A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-04217903 in Patients with Advanced Cancer
Trial Description
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of
tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte
growth factor receptor tyrosine kinase inhibitors. This research study is the first time
PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.
Eligibility Requirements
Inclusion Criteria:
- Advanced solid tumors, histologically proven at diagnosis which is refractory to
standard of care or for whom no standard of care therapy is available
- Adequate blood cell counts, normal kidney function, and performance status of 0 or 1
Exclusion Criteria:
- Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting
study treatment
- Prior stem cell transplant
- Active or unstable cardiac disease or heart attack within 12 months of starting
study treatment